Track market-moving stories before they get noisy

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Hims between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 25, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (""Hims" or the "Company") (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, during market hours, the Federal Trade Commission announced it had filed a lawsuit against Hims "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." On this news, Hims's stock price fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Hims class action, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Hims Securities Class Action Lawsuit:

What is the Hims securities fraud lawsuit about?

Faruqi & Faruqi, LLP has filed a securities class action lawsuit alleging that Hims & Hers Health, Inc. (NYSE: HIMS) made materially false and misleading statements to investors during the Class Period. The complaint alleges that the Company shared consumers' sensitive health information with third-party advertising platforms despite representing that its services maintain consumer privacy, and that the Company allegedly charged consumers for prescriptions almost immediately after intake form submission while telling consumers they would first be able to consult with a medical provider. The lawsuit further alleges that this conduct subjected Hims to regulatory scrutiny and made the Company reasonably likely to incur fees and penalties. On July 29, 2026, the Federal Trade Commission announced it had filed a lawsuit against Hims alleging these practices, and on that news Hims's stock price allegedly fell $4.32, or approximately 14.73%, to close at $25.00 per share on unusually heavy trading volume. As a result of the foregoing, the complaint alleges that Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NYSE: HIMS) on the NYSE exchange between August 4, 2025 and July 29, 2026, inclusive, may be eligible to participate in this class action lawsuit. Eligibility to participate in any potential recovery is not limited to investors who seek appointment as lead plaintiff; any investor who purchased Hims securities during the Class Period may be a class member. Eligible investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Investors with questions about their eligibility may wish to consult with counsel to better understand their rights and options in connection with this litigation.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who serves on behalf of all class members and plays an active role in directing the litigation, including working with counsel on case strategy and settlement decisions. Any investor who purchased Hims securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff, provided that motion is filed no later than November 2, 2026. Courts typically appoint the investor or group of investors with the largest financial interest in the litigation who also satisfy the requirements of Federal Rule of Civil Procedure 23 as lead plaintiff. Importantly, an investor need not seek appointment as lead plaintiff in order to participate in or share in any recovery that may result from the litigation. Investors who do not seek lead plaintiff status retain the right to remain members of the class and benefit from any judgment or settlement.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Hims securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320646

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLCPR Newswire

NEW YORK and NEW ORLEANS, Oct. 23, 2026

, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of Hims as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-hims/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 2, 2026.

>>>CLICK HERE for more information

About the Lawsuit

Hims & Hers Health and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 29, 2026, during market hours, the Federal Trade Commission ("FTC") announced that it had filed a lawsuit against the Company "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." The FTC further alleged that the Company fails to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'"

On this news, the price of Hims & Hers Health shares fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026, on unusually heavy trading volume.

The case is Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/hims--hers-health-inc-securities-fraud-class-action-result-of-deceptive-privacy-and-billing-practices-and-over-14-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918514.html

SOURCE Kahn Swick & Foti, LLC

In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $27.71, marking a -4.87% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.52%. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.

Prior to today's trading, shares of the company had lost 0.51% lagged the Medical sector's gain of 3.23% and was narrower than the S&P 500's loss of 1.21%.

Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on November 9, 2026. In that report, analysts expect Hims & Hers Health, Inc. to post earnings of $0.07 per share. This would mark year-over-year growth of 16.67%. In the meantime, our current consensus estimate forecasts the revenue to be $893.37 million, indicating a 49.15% growth compared to the corresponding quarter of the prior year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.79 per share and revenue of $3.22 billion. These totals would mark changes of -249.06% and +37.03%, respectively, from last year.

Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #3 (Hold).

The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 95, which puts it in the top 39% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Hims & Hers Health Inc. (NYSE:HIMS) urged a court to throw out a consumer deception lawsuit, asserting that plaintiffs ignored clear, upfront disclosures regarding data privacy, subscription charges, and cancellation policies.

The company argued that plaintiffs attempted to manufacture deception claims by disregarding the explicit terms and policies that consumers must acknowledge prior to purchasing.

Disclosures Contradict Telehealth Privacy AllegationsAccording to a lawsuit document dated Thursday, Plaintiffs contend that the telehealth provider promised discreet services while secretly sharing customer data with advertising platforms.

However, the company highlighted that every user must review and acknowledge its formal privacy policy before establishing an account.

Read Next

That official policy explicitly discloses that user data, including sensitive health-related platform activity, may go to marketing and advertising partners.

The policy also outlines third-party tracking and provides direct links to manage settings with advertising networks like Meta Platforms Inc. (NASDAQ:META) and Alphabet Inc. (NASDAQ:GOOGL). The company stressed that marketing descriptions of discreet care cannot displace these binding, clear disclosures.

Clear Subscription Terms Refute Billing AccusationsAddressing claims regarding misleading subscription billing, the company emphasized that its checkout system provides transparent pricing and terms.

Although plaintiffs cited promotional phrases like zero-dollar initial visits, the company’s checkout screen clearly outlines subsequent costs.

The platform specifies that consumers face a $147 fee for an initial 90-day medication supply upon receiving a prescription, alongside automatic recurring charges every 90 days thereafter until cancellation.

Refill shipments and charges occur ten days early, offering unambiguous timelines without promising any redundant payment authorizations.

Simple Cancellation Options Satisfy Federal RequirementsThe company also rejected accusations under the Restore Online Shoppers Confidence Act, noting that fixed-term installment contracts do not represent negative-option billing.

Even if the statute applies, the company demonstrated that it provides simple cancellation mechanisms. Customers can cancel subscriptions via phone, email, live chat, dedicated web accounts, and mobile applications.

Because the complaint fails to demonstrate ongoing violations or intentional misconduct, the company asserted that plaintiffs have no legal basis for injunctive relief or civil penalties under Federal Trade Commission standards.

Consequently, the company requested a complete dismissal of the action.

HIMS Price Action: Hims & Hers Health shares were down 2.03% at $28.54 at the time of publication on Friday, according to Benzinga Pro data.

Read Next

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

, /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.

Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now. 

Class Period: Aug. 4, 2025 – July 29, 2026
Lead Plaintiff Deadline: Nov. 2, 2026
Visit Hims Investigation Page: www.hbsslaw.com/hims
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895
Video: https://youtu.be/DZQWREfFVIM

Hims & Hers Health ($HIMS) Securities Class Action

The lawsuit is focused on the propriety of Hims' repeated assurances that "[w]e have developed and maintain policies and procedures with respect to health information and personal information that we use or disclose in connection with our operations, including the adoption of administrative, physical, and technical safeguards to protect such information."

The complaint alleges that Hims: (1) shared consumers' health information with third-party advertising platforms; (2) charges consumers for prescriptions almost immediately after they submit intake forms, despite telling them that they will be able to consult with a medical provider to find a treatment that is "right for them[;]" and (3) as a result, would be subject to heightened regulatory scrutiny and likely to incur fees and penalties.

What Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit Breakdown

The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC—alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California).

After an extensive investigation by the Commission, it contends that Hims engaged in:

Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching. Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form—long before receiving any consultation with a medical provider—while facing dark patterns and hidden cancellation options designed to prevent subscription termination. The market swiftly reacted, sending the price of Hims shares down $4.32 (-14.7%) and erasing over $970 million from the company's market capitalization in a single day.

"We're focused on whether Hims may have intentionally misled investors about its business practices, including the adequacy of its internal controls, and financial ramifications of the alleged misconduct," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”), have until Monday, November 2, 2026 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of Hims & Hers’ top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Hims & Hers class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-hims-hers-health-class-action-lawsuit-hims.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Hims & Hers operates as a health and wellness platform that connects consumers to licensed healthcare professionals.

The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims & Hers shared consumers’ health information with third-party advertising platforms; (ii) Hims & Hers charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them”; (iii) the foregoing conduct subjected Hims & Hers to regulatory scrutiny; (iv) as a result of the foregoing, Hims & Hers was reasonably likely to incur fees and penalties; and (v) as a result of the foregoing, defendants’ positive statements about Hims & Hers’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, the Federal Trade Commission allegedly announced it had filed a lawsuit against Hims & Hers “alleging that the telehealth provider shared consumers’ sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers’ privacy and deceives users about its billing and cancellation practices.” The Hims & Hers class action lawsuit further alleges that, according to the Federal Trade Commission’s complaint, Hims & Hers engages in other deceptive advertising practices, including failing to “clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is ‘right for them.’” Additionally, the Hims & Hers class action lawsuit alleges that the Federal Trade Commission’s complaint includes allegations that Hims and Hers “shared consumers’ sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. (‘Meta’) and Snap Inc. (‘Snap’).” On this news, the price of Hims and Hers shares declined nearly 15%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims & Hers securities during the Class Period to seek appointment as lead plaintiff in the Hims & Hers class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Hims & Hers class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Hims & Hers class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Hims & Hers class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800/851-7783
        [email protected]

New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.

NEW ORLEANS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company’s securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Get Help

Hims & Hers investors should visit us at https://claimsfiler.com/cases/nyse-hims-1/ or call toll-free (833) 538-3601. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Hims & Hers Health and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 29, 2026, during market hours, the Federal Trade Commission ("FTC") announced that it had filed a lawsuit against the Company "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." The FTC further alleged that the Company fails to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'"

On this news, the price of Hims & Hers Health shares fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026, on unusually heavy trading volume.

The case is Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.
(833) 538-3601

, /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.

So what: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Hims shared consumers' health information with third-party advertising platforms; (2) Hims charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected Hims to regulatory scrutiny; (4) as a result of the foregoing, Hims was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, defendants' positive statements about Hims' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Hims & Hers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 2, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Hims & Hers securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. 

[Click here for information about joining the class action]

On July 29, 2026, the Federal Trade Commission ("FTC") announced the filing of a lawsuit against Hims & Hers "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." According to the FTC complaint, Hims & Hers engages in other deceptive advertising practices, including failing to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'" The FTC complaint also includes allegations that Hims & Hers "shared consumers' sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. ('Meta') and Snap Inc. ('Snap')." 

On this news, Hims & Hers' stock price fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the fifteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $32.43.

A number of research analysts have recently commented on the stock. Citigroup decreased their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Truist Financial raised their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research note on Monday, August 24th. Finally, TD Cowen lifted their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th.

Read Our Latest Stock Report on Hims & Hers Health

Insider Buying and Selling In other news, insider Deborah M. Autor sold 16,773 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the sale, the insider directly owned 48,961 shares in the company, valued at approximately $1,363,563.85. This trade represents a 25.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the sale, the insider directly owned 313,964 shares in the company, valued at approximately $8,649,708.20. This trade represents a 7.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 130,443 shares of company stock valued at $3,731,426 over the last 90 days. 11.76% of the stock is currently owned by insiders. Institutional Trading of Hims & Hers Health Large investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after buying an additional 2,877,550 shares during the last quarter. State of Michigan Retirement System raised its stake in shares of Hims & Hers Health by 13.7% in the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after purchasing an additional 280,900 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $46,220,000. Principal Financial Group Inc. lifted its stake in Hims & Hers Health by 97.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock valued at $26,620,000 after acquiring an additional 632,282 shares in the last quarter. Finally, Bienville Capital Management LLC purchased a new position in Hims & Hers Health during the 2nd quarter worth $27,242,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Hims & Hers Health Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Expanded men’s health portfolio: Hims & Hers launched injectable and oral testosterone replacement therapies for eligible men, its largest men’s health expansion since entering the category. The broader product range could increase customer acquisition, engagement and revenue in a sizable market. Hims Expands Testosterone Care with Injectable and Oral TRT Positive Sentiment: European growth: The company launched an online weight-management service for men in Germany, allowing eligible users to receive prescriptions from European Union-licensed clinicians and ongoing support. The move expands Hims & Hers’ addressable market and helped drive a recent increase in the stock. Hims & Hers launches men’s weight care in Germany Neutral Sentiment: Membership momentum: A report said Hims & Hers is approaching three million members, suggesting continued platform adoption and potential operating leverage, although the milestone does not provide new formal financial guidance. Hims Is Reaching the Three Million Member Milestone Negative Sentiment: Regulatory and legal overhang: Multiple law firms publicized a securities class action against Hims & Hers following allegations in an FTC complaint concerning business practices, including privacy and billing issues. The lawsuit covers investors who purchased shares from August 4, 2025, through July 29, 2026, with a lead-plaintiff deadline of November 2, 2026. The allegations could increase legal costs, reputational risk and uncertainty around future operations; they have not been proven in court. Hims & Hers faces securities class action after FTC complaint Hims & Hers Health Price Performance HIMS opened at $29.19 on Thursday. The company’s 50 day simple moving average is $29.13 and its 200-day simple moving average is $28.99. The stock has a market capitalization of $6.81 billion, a P/E ratio of -46.33 and a beta of 2.44. Hims & Hers Health has a one year low of $13.74 and a one year high of $50.99. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 EPS. Sell-side analysts anticipate that Hims & Hers Health will post -0.16 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile (Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.

See Also Five stocks we like better than Hims & Hers Health GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall? Intercepting Growth: Karman Secures $218M Lockheed Martin Deal Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.

New York, New York--(Newsfile Corp. - October 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Hims shared consumers' health information with third-party advertising platforms; (2) Hims charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected Hims to regulatory scrutiny; (4) as a result of the foregoing, Hims was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, defendants' positive statements about Hims' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320236

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.

Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now. 

Class Period: Aug. 4, 2025 – July 29, 2026
Lead Plaintiff Deadline: Nov. 2, 2026
Visit Hims Investigation Page: www.hbsslaw.com/hims 
Direct Contact Email: [email protected] 
Firm Telephone: 844-916-0895
Video: https://youtu.be/DZQWREfFVIM

Hims & Hers Health ($HIMS) Securities Class Action

The lawsuit is focused on the propriety of Hims' repeated assurances that "[w]e have developed and maintain policies and procedures with respect to health information and personal information that we use or disclose in connection with our operations, including the adoption of administrative, physical, and technical safeguards to protect such information."

The complaint alleges that Hims: (1) shared consumers' health information with third-party advertising platforms; (2) charges consumers for prescriptions almost immediately after they submit intake forms, despite telling them that they will be able to consult with a medical provider to find a treatment that is "right for them[;]" and (3) as a result, would be subject to heightened regulatory scrutiny and likely to incur fees and penalties.

What Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit Breakdown

The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC—alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California).

After an extensive investigation by the Commission, it contends that Hims engaged in:

Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching.
Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form—long before receiving any consultation with a medical provider—while facing dark patterns and hidden cancellation options designed to prevent subscription termination.

The market swiftly reacted, sending the price of Hims shares down $4.32 (-14.7%) and erasing over $970 million from the company's market capitalization in a single day.

"We're focused on whether Hims may have intentionally misled investors about its business practices, including the adequacy of its internal controls, and financial ramifications of the alleged misconduct," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”).

CLICK HERE TO JOIN THE CASE

If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 2, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On July 29, 2026, the Federal Trade Commission (“FTC”), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them.” The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers’ health information with Meta, Snap and other third parties.

Following this news, the price of Hims & Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.

Based on the FTC allegations, the complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors, including that (1) the Company shared consumers’ health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them;” (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

CLICK HERE TO LEARN MORE

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/hims-hers-health-inc-class-action-investigation-learn-more-now/

New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.

New York, New York--(Newsfile Corp. - October 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Hims & Hers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 2, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Hims & Hers securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.        

[Click here for information about joining the class action]

On July 29, 2026, the Federal Trade Commission (“FTC”) announced the filing of a lawsuit against Hims & Hers “alleging that the telehealth provider shared consumers’ sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers’ privacy and deceives users about its billing and cancellation practices.”  According to the FTC complaint, Hims & Hers engages in other deceptive advertising practices, including failing to “clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is ‘right for them.’”  The FTC complaint also includes allegations that Hims & Hers “shared consumers’ sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. (‘Meta’) and Snap Inc. (‘Snap’).” 

On this news, Hims & Hers’ stock price fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Shares of Hims & Hers Health (HIMS) rose 5% on Tuesday after the telehealth company launched an online weight-management service for men in Germany, expanding its presence in Europe. The new offering allows patients to complete private online consultations and, if eligible, receive prescriptions from clinicians licensed in the European Union, along with ongoing support.

New York, New York--(Newsfile Corp. - October 20, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").

CLICK HERE TO JOIN THE CASE

If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 2, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties.

Following this news, the price of Hims & Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.

Based on the FTC allegations, the complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors, including that (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

CLICK HERE TO LEARN MORE

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/hims-hers-health-inc-class-action-investigation-learn-more-now/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319809

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Suit alleges Hims & Hers Health, Inc. failed to disclose key facts to investors from August 4, 2025 through July 29, 2026; lead plaintiff deadline is November 2, 2026

, /PRNewswire/ -- The Law Offices of Howard G. Smith today reported that a securities class action lawsuit is pending against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors who acquired its securities from August 4, 2025 through July 29, 2026. The Hims & Hers Health, Inc. case, Velanki v. Hims & Hers Health, Inc., et al., was filed on September 1, 2026 in the U.S. District Court for the Northern District of California (Case No. 3:26-cv-09313).

Investors with losses on Hims & Hers Health, Inc. securities can contact the Law Offices of Howard G. Smith about the Hims & Hers Health, Inc. lawsuit before the November 2, 2026 lead plaintiff deadline.

Key deadlines and dates for Hims & Hers Health, Inc. investors

Lead plaintiff deadline: November 2, 2026Class period: August 4, 2025 through July 29, 2026Complaint filed: September 1, 2026What happened?

On July 29, 2026, the Federal Trade Commission, joined by the State of Utah and Los Angeles County (representing California), filed a federal complaint against Hims & Hers Health in the U.S. District Court for the Northern District of California, alleging deceptive and unlawful privacy practices — including sharing sensitive user health data with third-party advertisers Meta Platforms (Facebook) and Snap via embedded tracking pixels and customer list matching despite marketing emphasizing strict privacy — as well as deceptive billing and subscription-cancellation practices.

On this news, shares of Hims & Hers fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, thereby injuring investors.

What is the Hims & Hers Health, Inc. lawsuit about?

The Hims & Hers Health, Inc. securities lawsuit alleges that, between August 4, 2025 and July 29, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Hims & Hers Health, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them"; (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result, defendants' positive statements about Hims & Hers Health, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

"The lawsuit against Hims & Hers Health, Inc. alleges that, among other things, the Company failed to tell investors that the Company shared consumers' health information with third-party advertising platforms. Hims & Hers Health, Inc. investors who bought during the class period may be able to pursue their losses, and the November 2, 2026 deadline is where that process begins," said Howard G. Smith of The Law Offices of Howard G. Smith.

Next steps for Hims & Hers Health, Inc. investors

Hims & Hers Health, Inc. investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims.

Lead plaintiff motions in the Hims & Hers Health, Inc. class action are due to the Court by November 2, 2026. For more information, visit the firm's website, email [email protected], or call (215) 638-4847.

If you purchased Hims & Hers Health, Inc. securities during the class period, you may retain counsel of your choice, or you may take no action and remain an absent class member. No class has been certified in the Hims & Hers Health, Inc. case so far.

Common questions from Hims & Hers Health, Inc. investors

Who is eligible? Investors who acquired Hims & Hers Health, Inc. securities from August 4, 2025 through July 29, 2026 and suffered losses may qualify for the class in the Hims & Hers Health, Inc. shareholder lawsuit.

What is the deadline? Lead plaintiff motions in the Hims & Hers Health, Inc. case are due by November 2, 2026.

Can I recover without being lead plaintiff? Yes, Hims & Hers Health, Inc. investors may take no action and remain absent class members.

Does it cost anything? The Law Offices of Howard G. Smith works on contingency, so investors pay no attorneys' fees unless there is a recovery, and any fees require court approval.

About The Law Offices of Howard G. Smith

The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.

Prior results do not guarantee a similar outcome.

Related links

Hims & Hers Health, Inc. case page, The Law Offices of Howard G. SmithComplaint: Velanki v. Hims & Hers Health, Inc., et al., U.S. District Court for the Northern District of CaliforniaFTC complaintHims & Hers Health, Inc. SEC filings index, EDGARThe Law Offices of Howard G. SmithContact
Howard G. Smith
The Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, PA 19020
Email: [email protected]
Telephone: (215) 638-4847
www.howardsmithlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View original content:https://www.prnewswire.com/news-releases/what-does-hims--hers-health-incs-14-73-stock-drop-mean-for-investors-the-law-offices-of-howard-g-smith-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302913207.html

SOURCE Law Offices of Howard G. Smith

, /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.

The complaint alleges that Hims shared consumers' sensitive health information with advertising platforms while representing that its services were private and secure, and engaged in deceptive billing practices.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information prior to the November 2, 2026 lead plaintiff deadline.

Why Was Hims & Hers Sued?

According to the complaint, defendants failed to disclose to investors that:

(1) the Company shared consumers' health information with third-party advertising platforms;
(2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;"
(3) the foregoing conduct subjected the Company to regulatory scrutiny;
(4) as a result, the Company was reasonably likely to incur fees and penalties; and
(5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why Did HIMS Stock Drop?

Plaintiff alleges that on July 29, 2026, during market hours, the Federal Trade Commission ("FTC") announced it had filed a lawsuit against Hims "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices."

According to the FTC's complaint, Hims engages in other deceptive advertising practices, including failing to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'" The complaint further alleges that, contrary to its promises that the platform is "100% online, private, and secure," Hims "shared sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. ('Meta') and Snap Inc. ('Snap')."

On this news, shares of Hims declined $4.32, or 14.73%, to close at $25.00 on July 29, 2026.

Who May Be Eligible to Participate in the Hims & Hers Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Hims securities between August 4, 2025 and July 29, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Shareholders who wish to lead the case should contact Robbins LLP prior to the November 2, 2026 lead plaintiff deadline. 

Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis.

Listen to our podcast.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history. 

"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Hims & Hers Health, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP

Investors seeking additional information about the Hims & Hers Health, Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

Attorney Advertising. Past results do not guarantee a similar outcome. 

SOURCE Robbins LLP

NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Hims shared consumers’ health information with third-party advertising platforms; (2) Hims charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them;” (3) the foregoing conduct subjected Hims to regulatory scrutiny; (4) as a result of the foregoing, Hims was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, defendants’ positive statements about Hims’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

San Diego, California--(Newsfile Corp. - October 19, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), have until Monday, November 2, 2026 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of Hims & Hers' top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Hims & Hers class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-hims-hers-health-class-action-lawsuit-hims.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Hims & Hers operates as a health and wellness platform that connects consumers to licensed healthcare professionals.

The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims & Hers shared consumers' health information with third-party advertising platforms; (ii) Hims & Hers charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them"; (iii) the foregoing conduct subjected Hims & Hers to regulatory scrutiny; (iv) as a result of the foregoing, Hims & Hers was reasonably likely to incur fees and penalties; and (v) as a result of the foregoing, defendants' positive statements about Hims & Hers' business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, the Federal Trade Commission allegedly announced it had filed a lawsuit against Hims & Hers "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." The Hims & Hers class action lawsuit further alleges that, according to the Federal Trade Commission's complaint, Hims & Hers engages in other deceptive advertising practices, including failing to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'" Additionally, the Hims & Hers class action lawsuit alleges that the Federal Trade Commission's complaint includes allegations that Hims and Hers "shared consumers' sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. ('Meta') and Snap Inc. ('Snap')." On this news, the price of Hims and Hers shares declined nearly 15%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims & Hers securities during the Class Period to seek appointment as lead plaintiff in the Hims & Hers class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Hims & Hers class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Hims & Hers class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Hims & Hers class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
Robbins Geller Rudman & Dowd LLP
Ken Dolitsky
Michael Albert
655 W. Broadway, Suite 1900, San Diego, CA 92101
800/851-7783
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319546

Source: Robbins Geller Rudman & Dowd LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

LOS ANGELES, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Investors in Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) have until November 2, 2026 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline. The Hims & Hers Health, Inc. case, Velanki v. Hims & Hers Health, Inc., et al., was filed on September 1, 2026 and is pending in the U.S. District Court for the Northern District of California (Case No. 3:26-cv-09313).

Investors who suffered losses on Hims & Hers Health, Inc. investments can contact Glancy about the Hims & Hers Health, Inc. class action to learn about potentially pursuing claims under the federal securities laws before the November 2, 2026 deadline.

Deadline and key dates for Hims & Hers Health, Inc. investors

Lead plaintiff deadline: November 2, 2026Class period: August 4, 2025 to July 29, 2026, inclusiveComplaint filed: September 1, 2026Court: U.S. District Court for the Northern District of California What happened?

On July 29, 2026, the Federal Trade Commission, joined by the State of Utah and Los Angeles County (representing California), filed a federal complaint against Hims & Hers Health in the U.S. District Court for the Northern District of California, alleging deceptive and unlawful privacy practices — including sharing sensitive user health data with third-party advertisers Meta Platforms (Facebook) and Snap via embedded tracking pixels and customer list matching despite marketing emphasizing strict privacy — as well as deceptive billing and subscription-cancellation practices.

On this news, shares of Hims & Hers fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, thereby injuring investors.

What does the Hims & Hers Health, Inc. complaint allege?

The Hims & Hers Health, Inc. securities lawsuit alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Hims & Hers Health, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) the Company shared consumers’ health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them”; (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result, defendants' positive statements about Hims & Hers Health, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Investors who purchased or otherwise acquired Hims & Hers Health, Inc. securities during the class period may move the Court no later than November 2, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

"The complaint filed against Hims & Hers Health, Inc. alleges that, among other things, the Company failed to disclose that the Company shared consumers’ health information with third-party advertising platforms. Investors who want to help lead this case must ask the Court by November 2, 2026, and that date is coming soon," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm that can help Hims & Hers Health, Inc. investors evaluate potential claims to recover their losses. Investors who wish to serve as lead plaintiff in the Hims & Hers Health, Inc. class action must move the Court by November 2, 2026. To learn more, visit the Hims & Hers Health, Inc. case page, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the Hims & Hers Health, Inc. class, you need not take any action at this time. You may retain counsel of your choice or take no action and remain an absent class member. No class has been certified yet in the Hims & Hers Health, Inc. case.

Frequently Asked Questions

Who is eligible? Investors who purchased or otherwise acquired Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 and suffered losses may be members of the proposed class in the Hims & Hers Health, Inc. shareholder lawsuit.

When is the Hims & Hers Health, Inc. lead plaintiff deadline? Motions to serve as lead plaintiff in the Hims & Hers Health, Inc. class action must be filed with the U.S. District Court for the Northern District of California by November 2, 2026.

What if I miss the Hims & Hers Health, Inc. deadline? After November 2, 2026, investors generally can no longer ask to be appointed lead plaintiff, but Hims & Hers Health, Inc. investors may still remain class members. Their ability to share in any future recovery does not depend on serving as lead plaintiff.

What is a lead plaintiff? In the Hims & Hers Health, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.

Does it cost anything to contact Glancy or participate in this action? Glancy represents Hims & Hers Health, Inc. investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery.

Why work with Glancy on the Hims & Hers Health, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Hims & Hers Health, Inc. class action. Prior results do not guarantee a similar outcome.

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

Hims & Hers Health, Inc. case page, Glancy Prongay Wolke & Rotter LLPComplaint: Velanki v. Hims & Hers Health, Inc., et al., U.S. District Court for the Northern District of CaliforniaFTC complaintHims & Hers Health, Inc. SEC filings index, EDGARGlancy Prongay Wolke & Rotter LLP Contact

Charles H. Linehan

Glancy Prongay Wolke & Rotter LLP

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

Email: [email protected]

Telephone: 310-201-9150 | Toll-free: 888-773-9224

www.glancylaw.com

Follow Glancy on LinkedIn, X, or Facebook.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC’s sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.

Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.  

“[w]e have developed and maintain policies and procedures with respect to health information and personal information that we use or disclose in connection…”

Class Period: Aug. 4, 2025 – July 29, 2026
Lead Plaintiff Deadline: Nov. 2, 2026
Visit Hims Investigation Page: www.hbsslaw.com/hims
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895
Video: https://youtu.be/DZQWREfFVIM

Hims & Hers Health ($HIMS) Securities Class Action

The lawsuit is focused on the propriety of Hims’ repeated assurances that “[w]e have developed and maintain policies and procedures with respect to health information and personal information that we use or disclose in connection with our operations, including the adoption of administrative, physical, and technical safeguards to protect such information.”

The complaint alleges that Hims: (1) shared consumers’ health information with third-party advertising platforms; (2) charges consumers for prescriptions almost immediately after they submit intake forms, despite telling them that they will be able to consult with a medical provider to find a treatment that is “right for them[;]” and (3) as a result, would be subject to heightened regulatory scrutiny and likely to incur fees and penalties.

What Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit Breakdown

The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC—alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California).

After an extensive investigation by the Commission, it contends that Hims engaged in:

Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching.Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers’ Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form—long before receiving any consultation with a medical provider—while facing dark patterns and hidden cancellation options designed to prevent subscription termination. The market swiftly reacted, sending the price of Hims shares down $4.32 (-14.7%) and erasing over $970 million from the company’s market capitalization in a single day.

“We’re focused on whether Hims may have intentionally misled investors about its business practices, including the adequacy of its internal controls, and financial ramifications of the alleged misconduct,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a1357de7-ea5f-404d-9f24-e963424789b7

Hims & Hers Health, Inc. (HIMS) Securities Class Action
Hagens Berman Highlights Lawsuit Targeting Hims & Hers Health, Inc. (HIMS) Over Alleged Misleading S...